Correspondence |

Flavocoxid and Hypersensitivity PneumonitisFlavocoxid and Hypersensitivity Pneumonitis FREE TO VIEW

Robert M. Levy, MD
Author and Funding Information

From Primus Pharmaceuticals, Inc.

Correspondence to: Robert Levy, MD, Primus Pharmaceuticals, Inc, 4725 N Scottsdale Rd, Ste 200, Scottsdale, AZ 85251; e-mail: rlevy@primusrx.com

Financial/nonfinancial disclosures: The author has reported to CHEST the following conflicts of interest: Dr Levy is Director of Clinical Development for Primus Pharmaceuticals, Inc, the manufacturer of Limbrel.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).

© 2011 American College of Chest Physicians

Chest. 2011;140(3):827-828. doi:10.1378/chest.11-0632
Text Size: A A A
Published online

To the Editor:

I have just become aware of the report in CHEST (October 2010) by Youssef and Tomic1 of a case of hypersensitivity pneumonitis associated with the use of our product, Limbrel (flavocoxid). I wish to thank them for their clear and concise description of the clinical presentation and appropriate treatment of this rare event.

Limbrel was first marketed nationally in April 2004. At that time, no instances of hypersensitivity pneumonitis had been reported in clinical trials or test marketing surveillance. By 2008, three cases had been reported, and the package insert was revised to reflect this complication. At the time of its most recent revision, in mid-2010, the package insert was again revised to reflect seven confirmed cases reported in post-marketing surveillance and through the US Food and Drug Administration’s MedWatch. As of that time, approximately 270,000 people had been exposed to the product as judged by the number of new prescriptions filled. Thus, the apparent incidence of hypersensitivity pneumonitis, as nearly as we can estimate it, is approximately 0.0023%, or somewhere around two to three per 100,000.

Given such a low incidence, it is unlikely that any individual physician would encounter the problem. The report by Youssef and Tomic should increase awareness of this rare event and enable more rapid institution of appropriate therapy and avoidance of unnecessary and inappropriate treatments.

Youssef JG, Tomic R. Limbrel (flavocoxid) as cause of hypersensitivity pneumonitis [abstract]. Chest. 2010;1384suppl 4:79A [CrossRef]




Youssef JG, Tomic R. Limbrel (flavocoxid) as cause of hypersensitivity pneumonitis [abstract]. Chest. 2010;1384suppl 4:79A [CrossRef]
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543